Our pipeline at a glance

Updated August 2, 2022. Our pipeline provides an overview of our late-stage clinical development programs and is updated quarterly.

Download Merck Pipeline PDF

Phase 2 83 Programs
  • Glioblastoma LENVIMA® (MK-7902) 1, 2
  • Pulmonary arterial hypertension MK-5475
  • Cardiovascular MK-2060
  • Hypercholesterolemia MK-0616
  • Nonalcoholic steatohepatitis (NASH) MK-3655
  • Nonalcoholic steatohepatitis (NASH) MK-6024
  • Chikungunya virus Vaccine V184
  • HIV 1 infection Islatravir+MK-8507 (MK-8591B) 4
  • Treatment resistant depression MK-1942
  • Schizophrenia MK-8189
  • Endometrial cancer TUKYSA® (MK-7119) 1
  • Small cell lung cancer favezelimab+ pembrolizumab (MK-4280A)
  • Head and neck squamous cell carcinoma V937
  • Advanced solid tumors quavonlimab+ pembrolizumab (MK-1308A)
  • Colorectal cancer quavonlimab+ pembrolizumab (MK-1308A)
  • Hepatocellular carcinoma quavonlimab+ pembrolizumab (MK-1308A)
  • Melanoma quavonlimab+ pembrolizumab (MK-1308A)
  • Small cell lung cancer quavonlimab+ pembrolizumab (MK-1308A)
  • Cutaneous squamous cell carcinoma V937
  • Breast cancer zilovertamab vedotin (MK-2140)
  • Gastric zilovertamab vedotin (MK-2140)
  • Hematological malignancies zilovertamab vedotin (MK-2140)
  • Non-small cell lung cancer zilovertamab vedotin (MK-2140)
  • Ovarian zilovertamab vedotin (MK-2140)
  • Pancreas zilovertamab vedotin (MK-2140)
  • Renal cell carcinoma favezelimab+ pembrolizumab (MK-4280A)
  • Breast cancer V937
  • Colorectal cancer TUKYSA® (MK-7119) 1
  • Melanoma cancer V937
  • Esophageal cancer ladiratuzumab vedotin (MK-6440) 1, 3
  • Gastric cancer ladiratuzumab vedotin (MK-6440) 1, 3
  • Head & neck squamous cell carcinoma ladiratuzumab vedotin (MK-6440) 1, 3
  • Prostate cancer Vibostolimab+pembrolizumab (MK-7684A)
  • Non-small cell lung cancer ladiratuzumab vedotin (MK-6440) 1, 3
  • Prostate cancer ladiratuzumab vedotin (MK-6440) 1, 3
  • Small cell lung cancer ladiratuzumab vedotin (MK-6440) 1, 3
  • Advanced solid tumors TUKYSA® (MK-7119) 1
  • Bladder cancer TUKYSA® (MK-7119) 1
  • Non-small cell lung cancer TUKYSA® (MK-7119) 1
  • Biliary tract cancer TUKYSA® (MK-7119) 1
  • Cervical cancer TUKYSA® (MK-7119) 1
  • Gastric TUKYSA® (MK-7119) 1
  • Melanoma ladiratuzumab vedotin (MK-6440) 1, 3
  • Hepatocellular carcinoma Vibostolimab+pembrolizumab (MK-7684A)
  • Head & neck squamous cell carcinoma Vibostolimab+pembrolizumab (MK-7684A)
  • Hematological malignancies nemtabrutinib (MK-1026)
  • Melanoma MK-4830
  • Colorectal cancer MK-4830 2
  • Non-small cell lung cancer favezelimab (MK-4280) 2
  • Hematological malignancies favezelimab (MK-4280) 2
  • Neoplasm Malignant MK-28701,3
  • Non-small cell lung cancer quavonlimab (MK-1308) 2
  • Non-small cell lung cancer MK-0482
  • Small cell lung cancer MK-4830 2
  • Non-small cell lung cancer MK-4830 2
  • Advanced solid tumors LYNPARZA® (MK-7339) 1, 3
  • Small cell lung cancer LENVIMA® (MK-7902) 1, 2
  • Prostate cancer LENVIMA® (MK-7902) 1, 2
  • Pancreas LENVIMA® (MK-7902) 1, 2
  • Biliary Tract LENVIMA® (MK-7902) 1, 2
  • Breast cancer ladiratuzumab vedotin (MK-6440)1,3
  • Renal cell carcinoma MK-4830 2
  • Neoplasm Malignant MK-56841
  • Hematologic malignancies Vibostolimab+pembrolizumab (MK-7684A)
  • Non-small cell lung cancer MK-58902
  • Advanced solid tumors KEYTRUDA® (MK-3475)
  • Esophageal cancer Vibostolimab+pembrolizumab (MK-7684A)
  • Endometrial cancer Vibostolimab+pembrolizumab (MK-7684A)
  • Colorectal cancer vibostolimab+pembrolizumab (MK-7684A)
  • Cervical cancer Vibostolimab+pembrolizumab (MK-7684A)
  • Breast cancer Vibostolimab+pembrolizumab (MK-7684A)
  • Biliary tract cancer Vibostolimab+pembrolizumab (MK-7684A)
  • Melanoma vibostolimab (MK-7684) 2
  • Overgrowth syndrome miransertib (MK-7075)
  • Rare cancers WELIREG® (MK-6482)3
  • Pancreatic cancer WELIREG® (MK-6482)3
  • Hepatocellular carcinoma WELIREG® (MK-6482)3
  • Colorectal cancer WELIREG® (MK-6482)3
  • Certain VHL tumors WELIREG® (MK-6482)3 (EU)
  • Biliary tract WELIREG® (MK-6482)3
  • Small cell lung cancer MK-58902
  • Solid tumors V937
  • Cytomegalovirus vaccine V160
Phase 3 30 Programs
  • Anti-Viral COVID-19 molnupiravir (MK-4482)1 (US)
  • HIV-1 infection doravirine+ islatravir​ (MK-8591A) 4
  • HIV-1 infection islatravir (MK-8591)
  • Non-small cell lung cancer LENVIMA® (MK-7902) 1, 2
  • Small cell lung cancer vibostolimab+pembrolizumab (MK-7684A)
  • Non-small cell lung cancer vibostolimab+pembrolizumab (MK-7684A)
  • Renal cell carcinoma (RCC) WELIREG® (MK-6482)3
  • Colorectal cancer favezelimab+ pembrolizumab (MK-4280A)
  • Non-small cell lung cancer Pembrolizumab subcutaneous (MK-3475)
  • Renal cell carcinoma (RCC) quavonlimab+ pembrolizumab (MK-1308A)
  • Small cell lung cancer LYNPARZA® (MK-7339) 1, 3
  • Non-small cell lung cancer LYNPARZA® (MK-7339) 1, 3
  • Colorectal cancer LYNPARZA® (MK-7339) 1, 3
  • Head & neck squamous cell carcinoma LENVIMA® (MK-7902) 1, 2
  • Melanoma cancer LENVIMA® (MK-7902) 1, 2
  • Gastric LENVIMA® (MK-7902) 1, 2
  • Esophageal cancer LENVIMA® (MK-7902) 1, 2
  • Colorectal LENVIMA® (MK-7902) 1, 2
  • Small cell lung cancer KEYTRUDA® (MK-3475)
  • Prostate cancer KEYTRUDA® (MK-3475)
  • Ovarian cancer KEYTRUDA® (MK-3475)
  • Mesothelioma cancer KEYTRUDA® (MK-3475)
  • Biliary tract cancer KEYTRUDA® (MK-3475)
  • Hepatocellular carcinoma KEYTRUDA® (MK-3475) (EU)
  • Gastric cancer KEYTRUDA® (MK-3475) (EU)
  • Cutaneous squamous cell carcinoma KEYTRUDA®
    (MK-3475) (EU)
  • Breast cancer TUKYSA® (MK-7119) 1
  • Respiratory syncytial virus (MK-1654)
  • Pulmonary Arterial Hypertension sotatercept (MK-7962)
  • Pneumococcal vaccine Adult (V116)
Under review 3 Programs
  • Anti-Viral COVID-19 molnupiravir (MK-4482) (EU)
  • Cough gefapixant (MK-7264) (US3, EU)
  • Pneumoconjugate vaccine Adult VAXNEUVANCE™ (V114) (JPN)

Therapeutic Key Areas

  • 1 - Being developed in collaboration.
  • 2 - Being developed in combination with KEYTRUDA.
  • 3 - Being developed as monotherapy and/or in combination with KEYTRUDA.
  • 4 - On FDA clinical hold

*In the pipeline chart included in the Company’s Form 10-Q for the quarterly period ended June 30, 2022, the Company inadvertently listed MK-1200 in Phase 2. MK-1200 is currently in Phase 1.

What do the phases of clinical trials mean?

Phase 1

Phase 1 clinical trials test the medicine or vaccine in a small group of 20 to 100 volunteers who are usually healthy, but not always.  The trial often takes place in a hospital. The goals are to determine:

  • If the medicine or vaccine is safe
  • If there are any side effects
  • How the medicine is broken down by and discharged from the body
  • How much medicine is needed and how often
  • For a vaccine, researchers see if it causes the desired response from the body’s immune system

Phase 1 trials an take from six months to one year to complete.


Phase 2

Phase 2 clinical trials test the vaccine or medicine in approximately 100 to 500 volunteers. In the case of medicines, volunteers usually have the disease or condition the investigational medicine is designed to treat. In vaccine studies, the volunteers are usually healthy. The goals of this phase are to determine:

  • How well the medicine or vaccine works
  • If the medicine or vaccine is safe
  • If there are any side effects
  • How much of the medicine or vaccine is needed and how often

Phase 2 trials can take from six months to one year or more to complete.


Phase 3

Phase 3 clinical trials can test the medicine or vaccine in 1,000 to 5,000 patient volunteers. For medicines, volunteers have the disease or condition the medicine is designed to treat. In vaccine studies, the volunteers may be healthy or have diseases or conditions. Phase 3 trials take place in hospitals, clinics or physician offices. Researchers closely monitor patients at regular intervals to:

  • Confirm that the medication or vaccine is effective
  • Identify and monitor side effects
  • Compare the medicine or vaccine to commonly used treatments
Phase 3 trials can take from one to four years to complete, depending on the disease, length of study and number of volunteers.

Under review

The application has been submitted to the regulatory authorities for review.


No Duty to Update

The information contained in this chart was current as of August 2, 2022. While this pipeline chart remains on the company’s website the company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the presentation and investors should not rely upon the information as current or accurate after August 2, 2022.

The chart reflects the company research pipeline as of August 2, 2022.

Candidates shown in Phase 3 include specific products. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism in a given therapeutic area. Phase 1 candidates are not shown.